Open Nav

Antidote Therapeutics, Inc.

  • Matthew Kalnik, Antidote Therapeutics, Inc.

Building awareness and fund-raising

  • Date:Wednesday, October 17
  • Time:11:00 AM - 11:15 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:We are a science-driven biopharmaceutical company developing novel nicotine-blocking therapies to treat diseases caused or worsened by nicotine. Our initial development strategy of treating existing disease to improve medical outcomes – rather than preventing future smoking-related illnesses that may occur decades later – is significantly different from how other drugs that target nicotine’s actions have been developed as aids to smoking cessation. The first indications for Antidote’s anti-nicotine drugs are the treatment of orphan vascular diseases in smokers. Unlike FDA-approved smoking cessation drugs, our candidates do not contain nicotine or interact with nicotine-receptors, our anti-nicotine therapeutics are designed to trap or eliminate nicotine in the blood, having the dual benefit of neutralizing nicotine’s direct, harmful effects on organs throughout the body and preventing nicotine from reaching the brain, thereby reducing the addictiveness of nicotine from tobacco products
  • Company
  • Company HQ City:Gaithersburg
  • Company HQ Country:United States
  • Company HQ State:Maryland                  
  • CEO/Top Company Official:Matthew W. Kalnik, PhD
  • Year Founded:2013
  • Main Therapeutic Focus:Cardiovascular
  • Lead Product in Development :ATI-1013
  • Development Phase of Primary Product:Pre-Clinical
  • Total Amount Raised to Date, In All Rounds:$9 million including grants
Matthew Kalnik
Antidote Therapeutics, Inc.